Author:
Frohna Paul,Lu Jianfeng,Eppler Steve,Hamilton Marta,Wolf Julie,Rakhit Ashok,Ling Jie,Kenkare-Mitra Saraswati R.,Lum Bert L.
Subject
Pharmacology (medical),Pharmacology
Reference28 articles.
1. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,744: dynamics of receptor inhibition in situ and antitumor effects in athymic mice;Pollack;J Pharmacol Exp Ther.,1999
2. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models;Higgins;Anticancer Drugs,2004
3. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma;Ng;Mol Cancer Ther.,2002
4. Phase I and pharmacological study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies;Hidalgo;J Clin Oncol.,2001
5. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer;Pérez-Soler;J Clin Oncol.,2004
Cited by
92 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献